Federal drug regulators warned Monday that more medications made at a troubled Framingham compounding pharmacy may be linked to fungal infections, including a second steroid and a heart drug given to transplant patients.

The disclosures raise the possibility that suspected contamination at New England Compounding Center may ­affect even more patients than the 14,000 nationwide previously estimated to be at risk.